Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 12/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556362 | 0.79 | RXFP1 (0.46) | RXFP1PPARGPPARDPPARANR1H4 | |
| SCHEMBL22556343 | 0.79 | RXFP1 (0.48) | RXFP1AKR1C3AKR1C2PPARGPPARD | |
| SCHEMBL22556296 | 0.78 | RXFP1 (0.44) | RXFP1AKR1C3AKR1C2PPARGPPARD | |
| SCHEMBL22556300 | 0.78 | RXFP1 (0.49) | RXFP1AKR1C3AKR1C2MAPK8TAS2R14 | |
| SCHEMBL22556551 | 0.77 | RXFP1 (0.46) | RXFP1AKR1C3AKR1C2MAPK8TAS2R14 | |
| SCHEMBL23701615 | 0.76 | RXFP1 (0.46) | RXFP1AKR1C3AKR1C2MAPK8TAS2R14 | |
| SCHEMBL22571348 | 0.76 | RXFP1 (0.48) | RXFP1AKR1C3AKR1C2MAPK8TAS2R14 | |
| SCHEMBL23112794 | 0.76 | RXFP1 (0.52) | RXFP1AKR1C3AKR1C2MAPK8TAS2R14 | |
| SCHEMBL22556322 | 0.76 | RXFP1 (0.45) | RXFP1AKR1C3AKR1C2MAPK8TAS2R14 | |
| SCHEMBL22556341 | 0.75 | RXFP1 (0.51) | RXFP1AKR1C3AKR1C2MAPK8TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885AKR1C3 4073/4885AKR1C2 3589/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885AKR1C3 4073/4885AKR1C2 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.